Stem Cell Investig. 2019; 6: 19.
1Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;
2Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran;
2Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran;
3Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
1Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;
2Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran;
3Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Contributions: (I) Conception and design: E Fathi, R Farahzadi; (II) Administrative support: E Fathi, R Farahzadi; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: R Farahzadi, N Rajabzadeh; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
#These authors contributed equally to this work.
Received 2018 Nov 11; Accepted 2019 Mar 17.
Recent developments in the stem cell biology provided new hopes in treatment of diseases and disorders that yet cannot be treated. Stem cells have the potential to differentiate into various cell types in the body during age. These provide new cells for the body as it grows, and replace specialized cells that are damaged. Since mesenchymal stem cells (MSCs) can be easily harvested from the adipose tissue and can also be cultured and expanded in vitro they have become a good target for tissue regeneration. These cells have been widespread used for cell transplantation in animals and also for clinical trials in humans. The purpose of this review is to provide a summary of our current knowledge regarding the important and types of isolated stem cells from different sources of animal models such as horse, pig, goat, dog, rabbit, cat, rat, mice etc. In this regard, due to the widespread use and lot of attention of MSCs, in this review, we will elaborate on use of MSCs in veterinary medicine as well as in regenerative medicine. Based on the studies in this field, MSCs found wide application in treatment of diseases, such as heart failure, wound healing, tooth regeneration etc.
Keywords: Mesenchymal stem cells (MSCs), animal model, cell-based therapy, regenerative medicine
Stem cells are one of the main cells of the human body that have ability to grow more than 200 types of body cells (1). Stem cells, as non-specialized cells, can be transformed into highly specialized cells in the body (2). In the other words, Stem cells are undifferentiated cells with self-renewal potential, differentiation into several types of cells and excessive proliferation (3). In the past, it was believed that stem cells can only differentiate into mature cells of the same organ. Today, there are many evidences to show that stem cells can differentiate into the other types of cell as well as ectoderm, mesoderm and endoderm. The numbers of stem cells are different in the tissues such as bone marrow, liver, heart, kidney, and etc. (3,4). Over the past 20 years, much attention has been paid to stem cell biology. Therefore, there was a profound increase in the understanding of its characteristics and the therapeutic potential for its application (5). Today, the utilization of these cells in experimental research and cell therapy represents in such disorders including hematological, skin regeneration and heart disease in both human and veterinary medicine (6).The history of stem cells dates back to the 1960s, when Friedenstein and colleagues isolated, cultured and differentiated to osteogenic cell lineage of bone marrow-derived cells from guinea pigs (7). This project created a new perspective on stem cell research. In the following, other researchers discovered that the bone marrow contains fibroblast-like cells with congenic potential in vitro, which were capable of forming colonies (CFU-F) (8). For over 60 years, transplantation of hematopoietic stem cells (HSCs) has been the major curative therapy for several genetic and hematological disorders (9). Almost in 1963, Till and McCulloch described a single progenitor cell type in the bone marrow which expand clonally and give rise to all lineages of hematopoietic cells. This research represented the first characterization of the HSCs (10). Also, the identification of mouse embryonic stem cells (ESCs) in 1981 revolutionized the study of developmental biology, and mice are now used extensively as one of the best option to study stem cell biology in mammals (11). Nevertheless, their application a model, have limitations in the regenerative medicine. But this model, relatively inexpensive and can be easily manipulated genetically (12). Failure to obtain a satisfactory result in the selection of many mouse models, to recapitulate particular human disease phenotypes, has forced researchers to investigate other animal species to be more probably predictive of humans (13). For this purpose, to study the genetic diseases, the pig has been currently determined as one the best option of a large animal model (14).
Stem cells, based on their differentiation ability, are classified into different cell types, including totipotent, pluripotent, multipotent, or unipotent. Also, another classification of these cells are based on the evolutionary stages, including embryonic, fetal, infant or umbilical cord blood and adult stem cells (15). shows an overview of stem cells classifications based on differentiation potency.
An overview of the stem cell classification. Totipotency: after fertilization, embryonic stem cells (ESCs) maintain the ability to form all three germ layers as well as extra-embryonic tissues or placental cells and are termed as totipotent. Pluripotency: these more specialized cells of the blastocyst stage maintain the ability to self-renew and differentiate into the three germ layers and down many lineages but do not form extra-embryonic tissues or placental cells. Multipotency: adult or somatic stem cells are undifferentiated cells found in postnatal tissues. These specialized cells are considered to be multipotent; with very limited ability to self-renew and are committed to lineage species.
Toti-potent cells have the potential for development to any type of cell found in the organism. In the other hand, the capacity of these cells to develop into the three primary germ cell layers of the embryo and into extra-embryonic tissues such as the placenta is remarkable (15).
The pluripotent stem cells are kind of stem cells with the potential for development to approximately all cell types. These cells contain ESCs and cells that are isolated from the mesoderm, endoderm and ectoderm germ layers that are organized in the beginning period of ESC differentiation (15).
The multipotent stem cells have less proliferative potential than the previous two groups and have ability to produce a variety of cells which limited to a germinal layer [such as mesenchymal stem cells (MSCs)] or just a specific cell line (such as HSCs). Adult stem cells are also often in this group. In the word, these cells have the ability to differentiate into a closely related family of cells (15).
Despite the increasing interest in totipotent and pluripotent stem cells, unipotent stem cells have not received the most attention in research. A unipotent stem cell is a cell that can create cells with only one lineage differentiation. Muscle stem cells are one of the example of this type of cell (15). The word uni is derivative from the Latin word unus meaning one. In adult tissues in comparison with other types of stem cells, these cells have the lowest differentiation potential. The unipotent stem cells could create one cell type, in the other word, these cells do not have the self-renewal property. Furthermore, despite their limited differentiation potential, these cells are still candidates for treatment of various diseases (16).
ESCs are self-renewing cells that derived from the inner cell mass of a blastocyst and give rise to all cells during human development. It is mentioned that these cells, including human embryonic cells, could be used as suitable, promising source for cell transplantation and regenerative medicine because of their unique ability to give rise to all somatic cell lineages (17). In the other words, ESCs, pluripotent cells that can differentiate to form the specialized of the various cell types of the body (18). Also, ESCs capture the imagination because they are immortal and have an almost unlimited developmental potential. Due to the ethical limitation on embryo sampling and culture, these cells are used less in research (19).
HSCs are multipotent cells that give rise to blood cells through the process of hematopoiesis (20). These cells reside in the bone marrow and replenish all adult hematopoietic lineages throughout the lifetime of the human and animal (21). Also, these cells can replenish missing or damaged components of the hematopoietic and immunologic system and can withstand freezing for many years (22).The mammalian hematopoietic system containing more than ten different mature cell types that HSCs are one of the most important members of this. The ability to self-renew and multi-potency is another specific feature of these cells (23).
Adult stem cells, as undifferentiated cells, are found in numerous tissues of the body after embryonic development. These cells multiple by cell division to regenerate damaged tissues (24). Recent studies have been shown that adult stem cells may have the ability to differentiate into cell types from various germ layers. For example, bone marrow stem cells which is derived from mesoderm, can differentiate into cell lineage derived mesoderm and endoderm such as into lung, liver, GI tract, skin, etc. (25). Another example of adult stem cells is neural stem cells (NSCs), which is derived from ectoderm and can be differentiate into another lineage such as mesoderm and endoderm (26). Therapeutic potential of adult stem cells in cell therapy and regenerative medicine has been proven (27).
For the first time in the late 1990s, CSCs were identified by John Dick in acute myeloid diseases. CSCs are cancerous cells that found within tumors or hematological cancers. Also, these cells have the characteristics of normal stem cells and can also give rise to all cell types found in a particular cancer sample (28). There is an increasing evidence supporting the CSCs hypothesis. Normal stem cells in an adult living creature are responsible for the repair and regeneration of damaged as well as aged tissues (29). Many investigations have reported that the capability of a tumor to propagate and proliferate relies on a small cellular subpopulation characterized by stem-like properties, named CSCs (30).
Embryonic connective tissue contains so-called mesenchymes, from which with very close interactions of endoderm and ectoderm all other connective and hematopoietic tissues originate, Whereas, MSCs do not differentiate into hematopoietic cell (31). In 1924, Alexander A. Maxi mow used comprehensive histological detection to identify a singular type of precursor cell within mesenchyme that develops into various types of blood cells (32). In general, MSCs are type of cells with potential of multi-lineage differentiation and self-renewal, which exist in many different kinds of tissues and organs such as adipose tissue, bone marrow, skin, peripheral blood, fallopian tube, cord blood, liver and lung et al. (4,5). Today, stem cells are used for different applications. In addition to using these cells in human therapy such as cell transplantation, cell engraftment etc. The use of stem cells in veterinary medicine has also been considered. The purpose of this review is to provide a summary of our current knowledge regarding the important and types of isolated stem cells from different sources of animal models such as horse, pig, goat, dog, rabbit, cat, rat, mice etc. In this regard, due to the widespread use and lot of attention of MSCs, in this review, we will elaborate on use of MSCs in veterinary medicine.
The isolation method, maintenance and culture condition of MSCs differs from the different tissues, these methods as well as characterization of MSCs described as (36). MSCs could be isolated from the various tissues such as adipose tissue, bone marrow, umbilical cord, amniotic fluid etc. (37).
Diagram for adipose tissue-derived mesenchymal stem cell isolation (3).
Diagram for bone marrow-derived MSCs isolation (33). MSC, mesenchymal stem cell.
Diagram for umbilical cord-derived MSCs isolation (34). MSC, mesenchymal stem cell.
Diagram for isolation of amniotic fluid stem cells (AFSCs) (35).
Diagram for MSCs characterization (35). MSC, mesenchymal stem cell.
The diversity of stem cell or MSCs sources and a wide aspect of potential applications of these cells cause to challenge for selecting an appropriate cell type for cell therapy (38). Various diseases in animals have been treated by cell-based therapy. However, there are immunity concerns regarding cell therapy using stem cells. Improving animal models and selecting suitable methods for engraftment and transplantation could help address these subjects, facilitating eventual use of stem cells in the clinic. Therefore, for this purpose, in this section of this review, we provide an overview of the current as well as previous studies for future development of animal models to facilitate the utilization of stem cells in regenerative medicine (14). Significant progress has been made in stem cells-based regenerative medicine, which enables researchers to treat those diseases which cannot be cured by conventional medicines. The unlimited self-renewal and multi-lineage differentiation potential to other types of cells causes stem cells to be frontier in regenerative medicine (24). More researches in regenerative medicine have been focused on human cells including embryonic as well as adult stem cells or maybe somatic cells. Today there are versions of embryo-derived stem cells that have been reprogrammed from adult cells under the title of pluripotent cells (39). Stem cell therapy has been developed in the last decade. Nevertheless, obstacles including unwanted side effects due to the migration of transplanted cells as well as poor cell survival have remained unresolved. In order to overcome these problems, cell therapy has been introduced using biocompatible and biodegradable biomaterials to reduce cell loss and long-term in vitro retention of stem cells.
Currently in clinical trials, these biomaterials are widely used in drug and cell-delivery systems, regenerative medicine and tissue engineering in which to prevent the long-term survival of foreign substances in the body the release of cells are controlled (40).
Today, the incidence and prevalence of heart failure in human societies is a major and increasing problem that unfortunately has a poor prognosis. For decades, MSCs have been used for cardiovascular regenerative therapy as one of the potential therapeutic agents (41). Dhein et al. [2006] found that autologous bone marrow-derived mesenchymal stem cells (BMSCs) transplantation improves cardiac function in non-ischemic cardiomyopathy in a rabbit model. In one study, Davies et al. [2010] reported that transplantation of cord blood stem cells in ovine model of heart failure, enhanced the function of heart through improvement of right ventricular mass, both systolic and diastolic right heart function (42). In another study, Nagaya et al. [2005] found that MSCs dilated cardiomyopathy (DCM), possibly by inducing angiogenesis and preventing cardial fibrosis. MSCs have a tremendous beneficial effect in cell transplantation including in differentiating cardiomyocytes, vascular endothelial cells, and providing anti-apoptotic as well angiogenic mediators (43). Roura et al. [2015] shown that umbilical cord blood mesenchymal stem cells (UCBMSCs) are envisioned as attractive therapeutic candidates against human disorders progressing with vascular deficit (44). Ammar et al., [2015] compared BMSCs with adipose tissue-derived MSCs (ADSCs). It was demonstrated that both BMSCs and ADSCs were equally effective in mitigating doxorubicin-induced cardiac dysfunction through decreasing collagen deposition and promoting angiogenesis (45).
There are many advantages of small animal models usage in cardiovascular research compared with large animal models. Small model of animals has a short life span, which allow the researchers to follow the natural history of the disease at an accelerated pace. Some advantages and disadvantages are listed in (46).
Despite of the small animal model, large animal models are suitable models for studies of human diseases. Some advantages and disadvantages of using large animal models in a study protocol planning was elaborated in (47).
Chronic wound is one of the most common problem and causes significant distress to patients (48). Among the types of tissues that stem cells derived it, dental tissuederived MSCs provide good sources of cytokines and growth factors that promote wound healing. The results of previous studies showed that stem cells derived deciduous teeth of the horse might be a novel approach for wound care and might be applied in clinical treatment of non-healing wounds (49). However, the treatment with stem cells derived deciduous teeth needs more research to understand the underlying mechanisms of effective growth factors which contribute to the wound healing processes (50). This preliminary investigation suggests that deciduous teeth-derived stem cells have the potential to promote wound healing in rabbit excisional wound models (49). In the another study, Lin et al. [2013] worked on the mouse animal model and showed that ADSCs present a potentially viable matrix for full-thickness defect wound healing (51).
Many studies have been done on dental reconstruction with MSCs. In one study, Khorsand et al. [2013] reported that dental pulp-derived stem cells (DPSCs) could promote periodontal regeneration in canine model. Also, it was shown that canine DPSCs were successfully isolated and had the rapid proliferation and multi-lineage differentiation capacity (52). Other application of dental-derived stem cells is shown in .
Diagram for application of dental stem cell in dentistry/regenerative medicine (53).
As noted above, stem cells have different therapeutic applications and self-renewal capability. These cells can also differentiate into the different cell types. There is now a great hope that stem cells can be used to treat diseases such as Alzheimer, Parkinson and other serious diseases. In stem cell-based therapy, ESCs are essentially targeted to differentiate into functional neural cells. Today, a specific category of stem cells called induced pluripotent stem (iPS) cells are being used and tested to generate functional dopamine neurons for treating Parkinson's disease of a rat animal model. In addition, NSC as well as MSCs are being used in neurodegenerative disorder therapies for Alzheimers disease, Parkinsons disease, and stroke (54). Previous studies have shown that BMSCs could reduce brain amyloid deposition and accelerate the activation of microglia in an acutely induced Alzheimers disease in mouse animal model. Lee et al. [2009] reported that BMSCs can increase the number of activated microglia, which effective therapeutic vehicle to reduce A deposits in AD patients (55). In confirmation of previous study, Liu et al. [2015] showed that transplantation of BMSCs in brain of mouse model of Alzheimers disease cause to decrease in amyloid beta deposition, increase in brain-derived neurotrophic factor (BDNF) levels and improvements in social recognition (56). In addition of BMSCs, NSCs have been proposed as tools for treating neurodegeneration disease because of their capability to create an appropriate cell types which transplanted. kerud et al. [2001] demonstrated that NSCs efficiently express high level of glial cell line-derived neurotrophic factor (GDNF) in vivo, suggesting a use of these cells in the treatment of neurodegenerative disorders, including Parkinsons disease (57). In the following, Venkataramana et al. [2010] transplanted BMSCs into the sub lateral ventricular zones of seven Parkinsons disease patients and reported encouraging results (58).
The human body is fortified with specialized cells named MSCs, which has the ability to self-renew and differentiate into various cell types including, adipocyte, osteocyte, chondrocyte, neurons etc. In addition to mentioned properties, these cells can be easily isolated, safely transplanted to injured sites and have the immune regulatory properties. Numerous in vitro and in vivo studies in animal models have successfully demonstrated the potential of MSCs for various diseases; however, the clinical outcomes are not very encouraging. Based on the studies in the field of stem cells, MSCs find wide application in treatment of diseases, such as heart failure, wound healing, tooth regeneration and etc. In addition, these cells are particularly important in the treatment of the sub-branch neurodegenerative diseases like Alzheimer and Parkinson.
The authors wish to thank staff of the Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Funding: The project described was supported by Grant Number IR.TBZMED.REC.1396.1218 from the Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Conflicts of Interest: The authors have no conflicts of interest to declare.
The rest is here:
Stem cell-based regenerative medicine - PMC - National Center for ...
- 001 Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- 002 Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- 003 Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- 004 Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- 005 Google to Invest in Regenerative Medicine [Last Updated On: May 5th, 2010] [Originally Added On: May 5th, 2010]
- 006 Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 [Last Updated On: May 22nd, 2010] [Originally Added On: May 22nd, 2010]
- 007 The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 008 The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 009 Stem Cell Therapy: Age of Human Cell Engineering is Born [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- 010 Using Stem Cells Scientists Grow a Rat Lung, Humans are Next [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 011 FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 012 FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 013 Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 014 Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 015 The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: January 18th, 2011] [Originally Added On: January 18th, 2011]
- 016 Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 7th, 2011] [Originally Added On: February 7th, 2011]
- 017 The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 018 Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 019 In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 020 In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 021 Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- 022 Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- 023 Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- 024 Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- 025 Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- 026 Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- 027 Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 028 Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 029 Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 030 Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 031 Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 032 Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 033 Dr Farshchian: Regenerative Medicine shows Potentials - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- 034 Mayo Clinic Regenerative Medicine Consult Service - Video [Last Updated On: October 16th, 2011] [Originally Added On: October 16th, 2011]
- 035 Regenerative Medicine and Applications of Stem Cell Research - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 036 The Future of Stem Cells and Regenerative Medicine - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 037 "You and Your Health" TV Show - Orthopedic Regenerative Medicine - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 038 Closing Remarks, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 039 Hearing Loss Research: CBR Exclusive! Stem Cells Explored as Cure for Hearing Loss - Video [Last Updated On: October 19th, 2011] [Originally Added On: October 19th, 2011]
- 040 An amazing story of stem cells, regenerative medicine and healing power: - Video [Last Updated On: October 19th, 2011] [Originally Added On: October 19th, 2011]
- 041 What is Regenerative Medicine? | Los Angeles | Hollywood | Beverly Hills - Video [Last Updated On: October 19th, 2011] [Originally Added On: October 19th, 2011]
- 042 A New Era in Regenerative Medicine - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- 043 McEwen Centre for Regenerative Medicine - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- 044 Retroviruses, Reproduction, and Regenerative Medicine: The Influence of Federal Funding - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 045 You and Your Heath TV Show - Orthopedic Regenerative Medicine Part 1 - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 046 TEDxPhoenix - Jane Maienschein - Stem Cells, Regenerative Medicine and Us - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 047 Regenerative Medicine: Pathways to Cure - Version 2.0 - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 048 Opening Remarks, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine - Video [Last Updated On: October 23rd, 2011] [Originally Added On: October 23rd, 2011]
- 049 Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- 050 Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- 051 Coast To Coast AM - 15.11.2011 - 4/4 - Regenerative Medicine/Dulce Base - Video [Last Updated On: November 17th, 2011] [Originally Added On: November 17th, 2011]
- 052 Coast To Coast AM - 15.11.2011 - 1/4 - Regenerative Medicine/Dulce Base - Video [Last Updated On: November 17th, 2011] [Originally Added On: November 17th, 2011]
- 053 Stem Cell Based Therapies for Blindness: David Hinton - CIRM Science Writer's Seminar - Video [Last Updated On: November 18th, 2011] [Originally Added On: November 18th, 2011]
- 054 Dr. Craig Saunders Discusses Stem Cells and Regenerative Medicine at the Evolution of Fat Workshop - Video [Last Updated On: November 24th, 2011] [Originally Added On: November 24th, 2011]
- 055 Coast To Coast AM: Regenerative Medicine / Dulce Base 11-15-2011 Download Link - Video [Last Updated On: November 24th, 2011] [Originally Added On: November 24th, 2011]
- 056 Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- 057 Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- 058 StemCellTV Talks to Elona Baum of the California Institute of Regenerative Medicine - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- 059 StemCellTV Talks to Michael Werner of Alliance for Regenerative Medicine at Meeting on the Mesa - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- 060 StemCellTV Talks to Morrie Ruffin of Alliance for Regenerative Medicine at Meeting on the Mesa - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- 061 Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 062 Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 063 2011 Summit: Harnessing Regenerative Medicine for US Service-members, Major General James K. Gilman - Video [Last Updated On: December 17th, 2011] [Originally Added On: December 17th, 2011]
- 064 Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 065 Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 066 Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 067 Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 068 Coast To Coast AM: 15.11.2011 - Regenerative Medicine/ Dulce Base - Video [Last Updated On: December 22nd, 2011] [Originally Added On: December 22nd, 2011]
- 069 Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video [Last Updated On: December 23rd, 2011] [Originally Added On: December 23rd, 2011]
- 070 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 071 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 072 Regenerative medicine company encouraged by heart failure trial [Last Updated On: January 28th, 2012] [Originally Added On: January 28th, 2012]
- 073 IndiaMART Leaders of Tomorrow AWards 2011 - Regenerative Medical Services Pvt Ltd - Video [Last Updated On: February 8th, 2012] [Originally Added On: February 8th, 2012]
- 074 American CryoStem Joins Alliance for Regenerative Medicine [Last Updated On: February 13th, 2012] [Originally Added On: February 13th, 2012]
- 075 ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from ... [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 076 Biomask: Improving Facial Burn Treatment for Soldiers in the Field [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- 077 Cytomedix to Showcase Aldagen's Promising Autologous Cell Therapy Technology at Two Regenerative Medicine Meetings [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- 078 Histogenics to Present at 7th Annual New York Stem Cell Summit [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- 079 BioTime CEO Michael D. West to Present at New York Stem Cell Summit [Last Updated On: February 18th, 2012] [Originally Added On: February 18th, 2012]
- 080 Makucell(TM) Announces Key Scientific Presentations and Launch of a Large, Multicenter Use Study of Asymmtate(TM) [Last Updated On: February 22nd, 2012] [Originally Added On: February 22nd, 2012]